



Additional file 5: Vector plots of AA-triggered PGD₂ and pLT dynamics derived from PBLs of MCAS and SM patients and healthy controls. Origin of arrows: basal eicosanoid release; arrowheads: AA-triggered eicosanoid release; grey arrows: control, healthy individuals (n = 20); black arrows: MCAD-M, MCAD patients without MCAD-specific medication (n = 9); red arrows: MCAD+M, MCAD patients with MCAD-specific medication (n = 12). **(A)** MCAS: MCAD patients with mast cell activation syndrome (n = 12); **(B)** SM: MCAD patients with systemic mastocytosis (n = 9). One SM patient was not depicted in the figure, because of extraordinarily high pLT release, both basal and after AA exposure (basal PGD₂ and pLT release: 531 and 258 pg/ml, respectively; AA-triggered PGD₂ and pLT release: 1810 and 843 pg/ml, respectively).